Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries
Coeptis Therapeutics Holdings (Nasdaq: COEP) has executed a Binding Letter of Intent to acquire NexGenAI Affiliates Network, a platform offering AI-powered marketing software and robotic process automation (RPA) capabilities. The acquisition aims to enhance Coeptis's operational efficiency while maintaining its focus on biopharmaceutical innovation. NexGenAI's suite of marketing tools utilizes AI and RPA to optimize campaigns, streamline workflows, and generate insights, particularly targeting the biotech, pharmaceutical, and multi-level marketing industries. The platform helps companies manage marketing campaigns while maintaining regulatory compliance.
Coeptis Therapeutics Holdings (Nasdaq: COEP) ha firmato una Lettera di Intenti Vincolante per acquisire la NexGenAI Affiliates Network, una piattaforma che offre software di marketing potenziato dall'IA e capacit脿 di automazione dei processi robotici (RPA). L'acquisizione mira a migliorare l'efficienza operativa di Coeptis, mantenendo allo stesso tempo un focus sull'innovazione biopharma. La suite di strumenti di marketing di NexGenAI utilizza IA e RPA per ottimizzare le campagne, semplificare i flussi di lavoro e generare intuizioni, con particolare attenzione ai settori biotech, farmaceutico e del marketing multilivello. La piattaforma aiuta le aziende a gestire le campagne di marketing, mantenendo la conformit脿 alle normative.
Coeptis Therapeutics Holdings (Nasdaq: COEP) ha ejecutado una Carta de Intenci贸n Vinculante para adquirir la NexGenAI Affiliates Network, una plataforma que ofrece software de marketing impulsado por IA y capacidades de automatizaci贸n de procesos rob贸ticos (RPA). La adquisici贸n tiene como objetivo mejorar la eficiencia operativa de Coeptis, manteniendo su enfoque en la innovaci贸n biofarmac茅utica. La suite de herramientas de marketing de NexGenAI utiliza IA y RPA para optimizar campa帽as, simplificar flujos de trabajo y generar informaci贸n, particularmente dirigida a las industrias biotecnol贸gica, farmac茅utica y de marketing multinivel. La plataforma ayuda a las empresas a gestionar campa帽as de marketing mientras mantiene el cumplimiento regulatorio.
旖旍棥韹办姢 韰岆澕頁嫳鞀� 頇�霐╈姢(Nasdaq: COEP)電� AI 旮半皹 毵堨紑韺� 靻岉攧韸胳洦鞏挫檧 搿滊磭 頂勲靹胳姢 鞛愲彊頇�(RPA) 旮半姤鞚� 鞝滉车頃橂姅 頂岆灚韽检澑 雱レ姢鞝燗I 鞝滍湸 雱ろ姼鞗岉伂毳� 鞚胳垬頃橁赴 鞙勴暅 甑啀霠� 鞛堧姅 鞚橅枼靹�毳� 觳搓舶頄堨姷雼堧嫟. 鞚措矆 鞚胳垬電� 旖旍棥韹办姢鞚� 鞖挫榿 須湪靹膘潉 頄レ儊鞁滍偆電� 瓴冹潉 氇╉憸搿� 頃橂┌, 靸濍獏瓿淀暀 鞝滌暯 順侅嫚鞐� 雽�頃� 歆戩霃勲ゼ 鞙犾頃╇媹雼�. 雱レ姢鞝燗I鞚� 毵堨紑韺� 霃勱惮 氇潓鞚� AI鞕� RPA毳� 頇滌毄頃橃棳 旌犿帢鞚胳潉 斓滌爜頇旐晿瓿�, 鞗岉伂頂岆毳� 臧勳唽頇旐晿氅�, 韸鬼瀳 靸濍獏瓿淀暀, 鞝滌暯 氚� 雼る嫧瓿� 毵堨紑韺� 靷办梾鞚� 雽�靸侅溂搿� 韱奠鞍霠レ潉 靸濎劚頃╇媹雼�. 鞚� 頂岆灚韽检潃 旮办梾鞚� 毵堨紑韺� 旌犿帢鞚胳潉 甏�毽晿霃勲 霃勳檧欤茧┌, 攴滌牅 欷�靾橂ゼ 鞙犾頃╇媹雼�.
Coeptis Therapeutics Holdings (Nasdaq: COEP) a sign茅 une Lettre d'Intention Engag茅e pour acqu茅rir le NexGenAI Affiliates Network, une plateforme offrant des logiciels de marketing aliment茅s par l'IA et des capacit茅s d'automatisation des processus robotiques (RPA). L'acquisition vise 脿 am茅liorer l'efficacit茅 op茅rationnelle de Coeptis tout en maintenant son attention sur l'innovation biopharmaceutique. La suite d'outils marketing de NexGenAI utilise l'IA et la RPA pour optimiser les campagnes, rationaliser les flux de travail et g茅n茅rer des insights, ciblant particuli猫rement les industries biotechnologique, pharmaceutique et de marketing 脿 plusieurs niveaux. La plateforme aide les entreprises 脿 g茅rer leurs campagnes marketing tout en garantissant la conformit茅 r茅glementaire.
Coeptis Therapeutics Holdings (Nasdaq: COEP) hat ein Verbindliches Absichtsschreiben zur 脺bernahme des NexGenAI Affiliates Network unterzeichnet, einer Plattform, die KI-unterst眉tzte Marketingsoftware und M枚glichkeiten zur Automatisierung von Gesch盲ftsprozessen (RPA) bietet. Die 脺bernahme zielt darauf ab, die operative Effizienz von Coeptis zu verbessern und gleichzeitig den Fokus auf biopharmazeutische Innovationen zu bewahren. NexGenAIs Suite von Marketing-Tools nutzt KI und RPA, um Kampagnen zu optimieren, Arbeitsabl盲ufe zu straffen und Einblicke zu generieren, insbesondere in den Bereichen Biotechnologie, Pharmazie und Mehrstufenmarketing. Die Plattform hilft Unternehmen, Marketingkampagnen zu verwalten und gleichzeitig die Einhaltung von Vorschriften sicherzustellen.
- Acquisition expands company's technological capabilities through AI and RPA integration
- Creates new revenue opportunities in biotech, pharma, and MLM marketing sectors
- Enhances operational efficiency through automation tools
- Potential deviation from core biopharmaceutical business focus
- Integration costs and resources required for new technology implementation
Insights
The acquisition of NexGenAI Affiliates Network represents a strategic pivot for Coeptis, diversifying beyond its core biopharmaceutical focus into AI-powered marketing solutions. While the financial terms remain undisclosed, this move could create new revenue streams through marketing services for biotech and pharma companies. However, investors should note several concerns: 1) The departure from core business focus might dilute resources from drug development programs, 2) The company's small market cap of
The acquisition targets an AI marketing platform with RPA capabilities, but several technical aspects warrant scrutiny. The platform's actual technological capabilities, competitive advantages and integration readiness aren't detailed. While AI-powered marketing tools are valuable, the biotech/pharma marketing space is already served by established players with sophisticated compliance-focused solutions. The emphasis on MLM industry applications raises questions about the sophistication and scalability of the technology. Without proven deployment history or technical specifications, it's challenging to assess whether this represents genuine innovation or merely follows the current AI hype cycle.
The Acquisition of NexGenAI Affiliates Network Expands Company's Capabilities and Drives Innovation, Operational Efficiency, and Opportunity for Growth
NexGenAI has developed a suite of innovative marketing tools that utilize AI and RPA to optimize campaigns, streamline workflows, and generate actionable insights. By acquiring these assets, Coeptis will bring these state-of-the-art solutions to companies seeking to overcome marketing challenges in competitive and highly regulated sectors, particularly in the biotech, pharmaceutical and multi-level marketing ("MLM") industries. These tools will help companies run smarter, more efficient marketing campaigns, saving time and resources while staying compliant with strict regulations.
Dave Mehalick, President and CEO of Coeptis Therapeutics commented, "We are excited to integrate NexGenAI Affiliates Network and groundbreaking AI and RPA-driven tools into our offerings. In industries like biotech, pharma, and MLM, where competition is so high and regulatory challenges are complex, having advanced tools to optimize marketing, streamline operations, and drive measurable results is critical."
Anshuman Dash, Lead Advisory behind the development of NexGenAI Affiliates Network commented, "The integration of NexGenAI's innovative AI-powered marketing solutions with Coeptis Therapeutics' forward-thinking approach marks a transformative step forward. This acquisition not only validates the cutting-edge technology we've developed but also aligns with Coeptis' mission to drive innovation in highly regulated industries. Together, we aim to revolutionize marketing strategies and operational efficiencies, ultimately delivering greater value to our partners and the industries we serve."
About Coeptis Therapeutics Holdings, Inc.
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively "Coeptis"), is a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis' product portfolio and rights are highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. Additionally, Coeptis is developing a universal, multi-antigen CAR T technology licensed from the University of
About NexGenAI:
NexGenAI Holding Group Inc., along with its majority-owned subsidiary NexGenAI Solutions Group, Inc., has developed a proprietary suite of advanced tools that power the NexGenAI Affiliates Network platform.聽 These tools, featuring AI-driven marketing software and robotic process automation capabilities, are designed to optimize campaigns, streamline operations, and provide actionable, data-driven insights. NexGenAI's platform provides cutting-edge AI-driven solutions that revolutionize business operations across various sectors. By leveraging artificial intelligence, NexGenAI empowers companies to automate processes, optimize efficiency, and drive sustainable growth. For more information on NexgenAI go to .
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of our management made in connection therewith contain or may contain "forward-looking statements" (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events or performance, and underlying assumptions, and other statements that are other than statements of historical facts. When we use words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, we are making forward-looking statements. Forward-looking statements are not a guarantee of future performance and involve significant risks and uncertainties that may cause the actual results to differ materially and perhaps substantially from our expectations discussed in the forward-looking statements. Factors that may cause such differences include but are not limited to: (1) the inability to maintain the listing of the Company's securities on the Nasdaq Capital Market; (2) the risk that the integration of the Deverra licensed assets will disrupt current plans and operations of the Company; (3) the inability to recognize the anticipated benefits of the newly-licensed assets, which may be affected by, among other things, competition, the ability of the Company to grow and manage growth economically and hire and retain key employees; (4) the risks that the Company's products in development or the newly-licensed assets fail clinical trials or are not approved by the
Contacts
Coeptis Therapeutics, Inc.
IR@coeptistx.com
View original content to download multimedia:
SOURCE Coeptis Pharmaceuticals, Inc.
FAQ
What is the purpose of Coeptis Therapeutics (COEP) acquiring NexGenAI Affiliates Network?
What technologies will COEP gain from the NexGenAI acquisition?
How will the NexGenAI acquisition benefit Coeptis Therapeutics (COEP)?
